First Tracks Biotherapeutics, Inc. TRAX R2KR3KPHARMA
Company Overview
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +131.84% |
| 6 Months: | +142.57% |
| 3 Months: | +4.81% |
| 1 Month: | +22.94% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)66.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRAX First Tracks Biotherapeutics, Inc. R2KR3KPHARMA | 44.05 | -9.35 | $1.57B | 0.00% | -44.64% | -41.80% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 51.28M | 52.81M |
| Operating Income | -51.28M | -52.81M |
| EBITDA | -50.67M | -52.69M |
| Interest Expense | - | - |
| Pretax Income | -47.20M | -50.48M |
| Tax Provision | - | - |
| Net Income | -47.20M | -50.48M |
| Diluted EPS | -1.36 | -1.45 |
| R&D Expense | 41.47M | 33.95M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 118.46M | 181.10M |
| Operating Income | -118.46M | -181.10M |
| EBITDA | -116.08M | -178.70M |
| Interest Expense | - | - |
| Pretax Income | -106.15M | -163.71M |
| Tax Provision | - | - |
| Net Income | -106.15M | -163.71M |
| Diluted EPS | -3.05 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 |
|---|---|---|
| Total Assets | 444.11M | 441.89M |
| Current Assets | 398.56M | 389.93M |
| Cash & Equivalents | 35.97M | 123.08M |
| Inventory | - | - |
| Receivables | - | - |
| Total Liabilities | 34.26M | 50.30M |
| Current Liabilities | 18.22M | 36.18M |
| Long Term Debt | - | - |
| Total Debt | 17.81M | 16.04M |
| Total Equity | 409.85M | 391.60M |
| Shares Outstanding | 34.75M | 34.75M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 |
|---|---|---|
| Operating Cash Flow | -93.00M | -125.81M |
| Investing Cash Flow | 144.75M | 95.40M |
| Financing Cash Flow | -87.09M | 117.52M |
| Capital Expenditure | -807.00K | -358.00K |
| Free Cash Flow | -93.81M | -126.16M |
| Net Change in Cash | -35.34M | 87.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | -25.9% | -41.8% |
| ROCE % | -27.8% | -44.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 8.88% | 3.17M | $101.11M |
| 2 | TCG Crossover Management, LLC | 8.10% | 2.90M | $92.22M |
| 3 | FMR, LLC | 5.75% | 2.05M | $65.42M |
| 4 | Affinity Asset Advisors, Llc | 5.69% | 2.03M | $64.72M |
| 5 | Blackrock Inc. | 5.50% | 1.96M | $62.54M |
| 6 | Trails Edge Capital Partners, LP | 4.24% | 1.51M | $48.22M |
| 7 | State Street Corporation | 4.23% | 1.51M | $48.19M |
| 8 | Vanguard Capital Management LLC | 4.06% | 1.45M | $46.24M |
| 9 | Jupiter Topco LLC | 3.05% | 1.09M | $34.76M |
| 10 | Vestal Point Capital, LP | 2.84% | 1.01M | $32.26M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TRAX
First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQNW81a0g3dnNSUmgxcGhCVS1UUTE0TG5mRXpIeHlVR3gyVVFwT2pBckZwMHhsM3FLc04wZXhfRlFPSVRMSXFWLW1QRWNHd0kzTmVEM0RZTmdZUUp5b0dLU3VGSXJ6SjFka0JEVnlRYWNSWFhzQVVBNmtGNUhnUUtGVmlxZFBDejJyYUNTYV…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1Vam5zNUVybTlTSExzNVBocXhKUjFTa3lLb2dvQktUU05oVWZQc285ZGdTVzZFRzdpRW9wUXdUdVZ0Y1owRXBJV0hJakxwc2Ra?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
TRAX Nov 2026 35.000 call (TRAX261120C00035000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBBcW81ZmRYNFI4ZGRzdkZDSDNMV2tQcE5fU3FtaF91X1FvcTNlc0lZSFA0UEFqRXBaU0FEbXBoWVQ5ZXJvRGctWHZZQnhmSElDMmdFd0FXM2pDZ1BKUXJNZlJXQmEtQQ?oc=5" target="_blank">TRAX Nov 2026 35.000 call (TR…
TRAX Apr 2027 25.000 call (TRAX270416C00025000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE02NS0yYkxycnBWVFVvTHJhQmluUVhOVV8wZGR5b3pUUG1xakdNREVUcVpPc3JLNUw0LUtRYWZJZ05fRUE1Mk9xcWt1Q3o3S0pMSllJSkozUE5EQWVtU3JnOERIYW5Idw?oc=5" target="_blank">TRAX Apr 2027 25.000 call (TR…
TRAX Apr 2027 60.000 call (TRAX270416C00060000) Stock Historical Prices & Data - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFBJUGxFUzBKRGd5bU1WdGNpOFNONF9VdzVKTlQ2OEhLbmhDeHl3YnB1N09iVGJqRjJtS3dpUEI3OHpWdi1zVU5VU3pNTHc2cWhIQlZUdE9XQm9nS2RENEVGTVRvMHktVTdtY2ZTS3pzVDM?oc=5" target="_blank">TRAX Apr 2027 60…
TRAX Oct 2026 15.000 put (TRAX261016P00015000) interactive stock chart - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE91RnN3UUdfZVl0VXBiOGtpZ3BTOUM0RjVtZjBNdXRRazBCQXRNX25KWmRfSWF1YVNoMzBwWEZzSFBkRU00bDc3Ni1NY2ExTmNsN0FLdmw1T1lPMy00LUNuMkgzRFFORGlkQ3BOVWdn?oc=5" target="_blank">TRAX Oct 2026 15.00…
TRAX — Frequently Asked Questions
What is the current share price of First Tracks Biotherapeutics, Inc. (TRAX)?
As of 2026-10-23 16:27 PDT, First Tracks Biotherapeutics, Inc. (TRAX) trades at $44.05 on NasdaqGS. Its 52-week range is $15.32 to $47.92.
What is the market capitalisation of TRAX?
First Tracks Biotherapeutics, Inc. (TRAX) has a market capitalisation of $1.57B on NasdaqGS.
What is the P/E ratio of TRAX?
TRAX trades at a trailing price-to-earnings (P/E) ratio of -9.35. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 8.09.
What is the return on equity (ROE) of TRAX?
TRAX has a return on equity (ROE) of -41.80%. Its return on capital employed (ROCE) is -44.64%.
Is TRAX a good stock to buy?
This page provides a data-driven analysis of First Tracks Biotherapeutics, Inc. (TRAX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.